Optimal Location of Nerve Block to Minimize Perioperative Opioid Administration in ACL Surgery: Comparing True Adductor Canal to Proximal Block

NYU Langone Health

Status and phase: Completed; Phase 4

Conditions: ACL Surgery

Treatments: Drug: ACB within true AC with bupivacaine 0.5% 20cc; Drug: ACB proximal to true AC with bupivacaine 0.5% 20cc

Study type: Interventional

Funder types: Other

Identifiers

NCT03401450

17-01602

Details and patient eligibility

About

This is a prospective, randomized, single blinded trial involving human subjects. The goal of this study is to determine an optimal location (proximal or distal) for the nerve block and whether it will make a difference in how much opioid the patient will receive during and after surgery. Ultrasound will identify the adductor canal and the proximal end of the adductor canal/apex of the femoral triangle to determine the location of the blocks.

Their will be two randomized groups: 1. ACB within true AC with bupivacaine 0.5% 20cc2. ACB proximal to true AC with bupivacaine 0.5% 20cc

Enrollment: 69 patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients undergoing unilateral, ACL surgery with allograft.
• Patients who consent to be randomized.
• Patients must be English proficient.

Exclusion criteria

• Patients younger than 18 or older than 75 years of age;
• Patients with a history of chronic pain or who are taking medications intended to treat chronic pain such as strong opioids;
• Patients with history of neurologic disorder that can interfere with pain sensation;
• Patients with a history of drug or alcohol abuse;
• Patients who are unable to understand or follow instructions;
• Patients with an allergy or a contraindication to any of the medications used in the study, or patients with a contraindication to any of the study procedures;
• Patients with severe liver disease, renal insufficiency, congestive heart failure, and/ or significant heart disease;
• Patients with a BMI over 42;
• Any patient that the investigators feel cannot comply with all study related procedures.
• Patients who do not tolerate Percocet.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

69 participants in 2 patient groups

ACB within true AC with bupivacaine

Active Comparator group

Description:

The patients will receive an ultrasound-guided single injection adductor canal block with 20 mL of 0.5% bupivacaine

Treatment:

Drug: ACB within true AC with bupivacaine 0.5% 20cc

ACB proximal to true AC with bupivacaine

Active Comparator group

Description:

The patients will receive an ultrasound-guided single injection femoral triangle block with 20 mL of 0.5% bupivacaine

Treatment:

Drug: ACB proximal to true AC with bupivacaine 0.5% 20cc